TABLE 4.
Microbiological outcomes of evaluable patients treated with SUL-DUR by SUL-DUR MIC of ABC baseline isolates in ATTACK
| SUL-DUR MIC of baseline ABC (µg/mL) | |||||
|---|---|---|---|---|---|
| Total, N (%) | 0.5 | 1 | 2 | 4 | |
| All evaluable patients who received SUL-DURa | |||||
| Number of patients | 87 | 5 | 28 | 43 | 11 |
| (Presumed) Eradication | 63 (72%) | 3 (60%) | 19 (68%) | 32 (75%) | 9 (82%) |
| (Presumed) Persistence | 18 (21%) | 2 (40%) | 5 (18%) | 10 (23%) | 1 (9%) |
| Indeterminate | 6 (7%) | 0 | 4 (14%) | 1 (2%) | 1 (9%) |
| Part A CRABC m-MITT | |||||
| Number of patientsb | 61 | 4 | 22 | 28 | 7 |
| (Presumed) Eradication | 42 (69%) | 2 (50%) | 14 (64%) | 20 (71%) | 6 (86%) |
| (Presumed) Persistence | 15 (24%) | 2 (50%) | 5 (23%) | 8 (28%) | 0 |
| Indeterminate | 4 (6%) | 0 | 3 (14%) | 0 | 1 (14%) |
| Part B | |||||
| Number of patients | 26 | 1 | 6 | 15 | 4 |
| (Presumed) Eradication | 21 (81%) | 1 (100%) | 5 (83%) | 12 (80%) | 3 (75%) |
| (Presumed) Persistence | 3 (12%) | 0 | 0 | 2 (13%) | 1 (25%) |
| Indeterminate | 2 (7%) | 0 | 1 (7%) | 1 (7%) | 0 |
a
Patients in the CRABC m-MITT with SUL-DUR MIC < 8 µg/mL.
b
The SUL-DUR arm in Part A CRABC m-MITT consisted of 61 patients for this analysis because the SUL-DUR MIC was not determined for two baseline ABC isolates that were not sent to the central laboratory. Presumed eradication = patient experienced clinical cure and there was no microbiological sample taken. Presumed persistence = patient experienced clinical failure and there was no microbiological sample taken. Sulbactam-durlobactam was tested as a titration of sulbactam in the presence of 4 µg/mL durlobactam.